Oliver Loxley


Bennett Jones Oliver Loxley Partner Vancouver, Toronto 604.891.5112 / 416.777.5497 (Toronto) loxleyo@bennettjones.com Education University of British Columbia, BSc (Hons) University of British Columbia, JD Bar Admissions New York Ontario British Columbia Oliver's practice is focused on corporate finance, including debt and equity capital markets, institutional lending and other capital raising activities. He represents issuers, underwriters, financial sponsors and other investors in domestic and international transactions. Overview Oliver's recent experience includes initial public offerings, debt issuances (high yield and investment grade) and equity-linked transactions—often with a significant cross-border component—for prominent companies, investment banks and private equity firms. He also regularly acts on restructurings, liability management transactions, mergers and acquisitions and other strategic matters. Examples of Oliver's experience include: Initial purchasers of airline's C$850,000,000 secured high yield notes offering. Mountain Province Diamonds in its issuance of US$195,000,000 of 9.000% Senior Secured Second Lien Notes due 2025. Medicus Pharma in its US initial public offering and listing on Nasdaq. Initial purchasers of satellite company's US$150,000,000 high yield notes offering. Borrower in its US$400,000,000 credit agreement with alternative lenders. The Watermill Group in the financing of its acquisition of Weston Forest Products Inc. Underwriters of automotive company's US$2,875,000,000 convertible notes offering. Prior to joining Bennett Jones, Oliver practised at a leading international law firm based in New York. Select Experience • The Initial Consenting Senior Secured Noteholders of Sherritt International Corporation, a nickel and cobalt producer and refiner, in connection with a note exchange and recapitalization by way of Court-approved plan of arrangement • Waste Connections in its C$500-million inaugural offering of senior notes • Medicus Pharma Ltd., in its acquisition of Antev Limited, a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate, for consideration of up to approximately US$75 million.

Partner